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ABSTRACT 
 
 
Garrido, Christian M. M.S., Department of Biochemistry and Molecular Biology, Wright 
State University, 2018. Avicin is a potent sphingomyelinase inhibitor that blocks K-Ras 
plasma membrane interaction and its oncogenic activity. 
 
Ras proteins are small GTPases that regulate cell growth, differentiation and apoptosis. 
There are three main isoforms: H-, N-, and K-Ras in mammalian cells, and they cycle 
between an active GTP- and inactive GDP-bound states. Constitutively active Ras 
mutations are found in ~15% of all human cancers. Of those, oncogenic K-Ras is found in 
~98% of pancreatic, ~52% colorectal, and ~32% of lung cancers. In nearly 30 years since 
its discovery, there are no anti-K-Ras drugs currently available for clinical use. Since K-Ras 
must be localized to the plasma membrane (PM) for its full biological activity, targeting K-
Ras PM interaction is a valid therapeutic approach for blocking its oncogenic activity. Our 
study identifies that avicin, a family of natural plant-derived triterpenoid saponins from 
Acacia victoriae, could be an anti-K-Ras-specific cancer drug. Avicin mislocalizes K-Ras 
from the PM to lysosomes and endomembranes, blocks its downstream signaling and 
reduces proliferation of K-Ras-addicted cancer cells. In addition, avicin redistributes 
phosphatidylserine (PS) from the inner-leaflet of the PM. We further identified that avicin 
mislocalizes K-Ras and PS from the PM through inhibiting sphingomyelinases (SMases), 
enzymes that hydrolyze of sphingomyelin (SM) to ceramide (Cer). Avicin increases cellular 
SM levels by disrupting SMase activity, their cellular localization and expression level. 
 iv 
Furthermore, supplementation with exogenous Cer returns K-Ras and PS to the PM, 
suggesting cellular balance of SM and Cer is important for K-Ras and PS interaction with 
the PM. Taken together, we have identified that avicin is a new potent SMase inhibitor 
and an anti-K-Ras drug, and that targeting cellular SM/Cer balance could be a good 
starting point to develop anti-K-Ras cancer drugs. 
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INTRODUCTION 
I. Ras 
The RAS genes encode 21kDa proteins that belong to a family of small GTPases and consist 
of three main isoforms in mammalian cells: H-Ras, N-Ras and K-Ras, which encodes two 
alternative splice variants, K-Ras4A and K-Ras4B. From herein, K-Ras4B will be referred to 
as K-Ras.  
A. Ras structure and membrane trafficking 
i. Functional domains 
Ras protein consists of a conserved G domain (amino acid (a.a.) residues 1-166) and 
hypervariable region (HVR) (a.a. 167-189) (Figure 1). The G domain is made up of an 
effector lobe (a.a. 1-86) and an allosteric lobe (a.a.  87-166). The effector lobe is 100% 
conserved within all Ras isoforms and are involved in GTP/GDP loading, downstream 
effector binding, and associates with GTPase activating proteins (GAPs) and guanine 
nucleotide exchange factors (GEFs) (Quilliam et al., 1996; Tsai et al., 2015). The effector 
lobe contains switch I and switch II regions, which undergo large conformational changes 
upon GTP/GDP nucleotide exchanges, resulting in the downstream effector binding 
(Spencer-Smith & O'Bryan, 2017). The allosteric lobe is involved in Ras dimerization  
(Parker & Mattos, 2015). The HVR is the least conserved region (15%) within Ras isoforms 
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and is the site for Ras post-translational modifications, which allow Ras trafficking to and 
interacting with the plasma membrane (PM).  
ii. Post-translational modifications and membrane trafficking 
All Ras isoforms possess a C-terminal CAAX motif in their HVR, which is required for Ras 
trafficking to the PM (Hancock, Magee, Childs, & Marshall, 1989; Hancock, Paterson, & 
Marshall, 1990; Spencer-Smith & O'Bryan, 2017). The CAAX motif consists of a Cys 
residue, two aliphatic amino acids, and one amino acid from Met, Cys, Ser, Ala or Gln.  
Once Ras is translated, the Cys in the CAAX motif gets farnesylated by farnesyltransferase, 
allowing Ras interaction with the endoplasmic reticulum (ER). On the ER, the -AAX 
residues is cleaved by Ras converting CAAX endopeptidase 1 (Rce1), and the now C-
terminal farnesylated Cys gets methylated by isoprenylcysteine 
carboxylmethytransferase (ICMT). After the methylation, additional Ras isoform-specific 
lipidation sites are post-translationally modified to enhance Ras PM association. H-Ras 
and N-Ras are directed from the ER to the Golgi, where H-Ras (Cys 181 and Cys 184) and 
N-Ras (Cys 181) are palmitoylated and traffics to the PM via classical exocytic pathway. 
Also, H- and N-Ras traffics between the Golgi and PM through 
palmitoylation/depalmitoylation of these sites. However, K-Ras does not possess these 
additional lipidation sites. Instead, K-Ras contains a polybasic domain of a stretch of six 
positively charged lysine residues in its HVR, which allows electrostatic interaction with 
phosphatidylserine (PS), an anionic phospholipid, at the inner leaflet at the PM (Hancock 
et al., 1989; Hancock et al., 1990; Zhou & Hancock, 2018) (Figure 3). The forward 
trafficking of K-Ras from the ER to the PM is not fully characterized. Once K-Ras interacts  
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Ras conserved G domain consists of an effector lobe (containing Switch I and Switch II 
regions) and an allosteric lobe. Amino acid sequences of the HVR are shown for H-Ras, 
N-Ras, K-Ras4A and K-Ras4B isoforms with post-translational modification sites 
(labeled in color). All Ras isoforms possess a CAAX motif at the C-terminus of the HVR. 
K-Ras4B (bold) is the only Ras isoform with a polybasic domain made up of positively 
charged lysine residues. Figure adapted from (Spencer-Smith and O’Bryan, 2017). 
Figure 1. Schematic of Ras functional domains 
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with the PM, this interaction is maintained via endocytic recycling through the recycling 
endosome (Schmick et al., 2014) (Figure 2). 
B. Ras function and activity 
Ras must be localized to the PM for their full biological activity (Willumsen, Christensen, 
Hubbert, Papageorge, & Lowy, 1984). GTP and GDP binding play an important role in the 
regulation of Ras function (Kiel et al., 2009). Ras proteins function as molecular switches 
and cycle between an active GTP-bound state and inactive GDP-bound state (Spencer-
Smith & O'Bryan, 2017). Ras activation is initiated in response to upstream growth factor 
binding to epidermal growth factor receptors or receptor tyrosine kinases (Papke & Der, 
2017). Upon growth factor stimulation, guanine nucleotide exchange factors (GEFs) are 
recruited to the PM and activates GDP-Ras by releasing GDP and facilitate binding of GTP 
(Hancock, 2003) (Figure 4). Conversely, GTP-Ras is inactivated by binding of GTPase 
activating proteins (GAPs) to Ras, enhancing its intrinsic GTPase activity and mediates the 
conversion of GTP to GDP (Baines, Xu, & Der, 2011; Spencer-Smith & O'Bryan, 2017) 
(Figure 4). Activated GTP-Ras stimulates its downstream effectors regulating numerous 
essential signaling pathways such as cell proliferation, migration, differentiation and 
motility (Spencer-Smith and O’Bryan, 2017) (Figure 4). Two main cellular signaling 
pathways activated by Ras are mitogen-activated protein kinases (MAPK) and 
phosphoinositide-3 kinase (PI3K) pathways, which are involved in cell growth and survival 
(Zenonos & Kyprianou, 2013). On the PM, ~40% of Ras proteins are spatially segregated 
into nano-scale clusters, termed nanoclusters, and the rest (~60%) exists in a monomer 
form. 
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(1) All Ras isoforms are farnesylated at the Cys residue in their CAAX motif. (2) 
Farnesylated Ras interacts with the ER where -AAX is cleaved and the now C-terminal 
Cys is methylated. (3A) H-Ras and N-Ras are directed to the Golgi where they are 
palmitoylated and (4A) cycle to and from the PM for maintaining their activity. (3B) 
K-Ras is directed to the PM and (4B) cycle to and from recycling endosomes for 
maintaining their activity. Figure adapted from (Spencer-Smith and O’Bryan, 2017). 
Figure 2. Ras post-translational modifications and membrane trafficking 
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K-Ras is the only Ras isoform which contains a stretch of six positively charged lysine 
residues in its HVR termed the polybasic domain. This polybasic domain serves as a 
secondary membrane targeting signal which interacts with the negatively charged 
phospho-head group of PS indicated in yellow. 
Figure 3. K-Ras polybasic domain interacts with PS 
 
 
7 
Each nanocluster is ~0.5nm in diameter and contains ~7 Ras proteins (Cho & Hancock, 
2013; Tian et al., 2007). Previous studies showed that nanoclustered GTP-Ras, but not a 
monomer GTP-Ras, is able to recruit and interact with its downstream effector proteins 
(Tian et al., 2007). Furthermore, increasing or decreasing the fraction of nanoclustered 
GTP-Ras elevates or abrogates Ras signal transduction, respectively, suggesting that Ras 
nanoclusters serve as a platform for Ras signal transduction (Cho & Hancock, 2013; Tian 
et al., 2007). 
C. Ras mutations in cancer 
Ras mutations occur at one of three missense mutated codons: G12, G13 and Q61 (Prior, 
Lewis, & Mattos, 2012). Single mutations at G12, G13 or Q61 lead to impaired activity of 
GAPs, which forces mutated Ras in a constitutively active GTP-bound state. Constitutively 
active Ras promotes sustained downstream signaling associated with cancer cell growth, 
differentiation, and survival (Lu, Jang, Gu, Zhang, & Nussinov, 2016; Spencer-Smith & 
O'Bryan, 2017) (Figure 5). 
Ras are the most frequently mutated oncogenes, mutated in 15-20% of all human cancers 
(Stephens, Yi, Kessing, Nissley, & McCormick, 2017). K-Ras is the predominately mutated 
Ras isoform making up 85% of all Ras mutations (Hobbs, Der, & Rossman, 2016). K-Ras is 
frequently mutated in 98% pancreatic adenocarcinomas, 52% colorectal carcinomas and 
32% lung carcinomas (Hobbs et al., 2016). In contrast, mutations in H-Ras (4%) and N-Ras 
(11%) are less common (Hobbs et al., 2016). Despite early studies focused primarily on H-
Ras, more attention has been drawn to K-Ras (Johnson et al., 2017).  
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D. Approaches for anti-K-Ras drug discovery 
 
Cancers may require the sustained expression and activation of a single mutated 
oncogene, a phenomenon called oncogene addiction (A. Singh et al., 2009; Weinstein & 
Joe, 2006). Previous studies identified a population of non-small cell lung cancer cells 
(NSCLCs) and pancreatic ductal adenocarcinoma cells (PDACs) requires oncogenic K-Ras 
activity for their cell growth and survival, termed as K-Ras-dependent or -addicted (Hayes 
et al., 2016; A. Singh et al., 2009). Therefore, blocking oncogenic K-Ras activity in these K-
Ras-dependent cancers is a rational strategy for targeting cancer cells expressing 
oncogenic K-Ras.  
 
There have been many attempts to develop anti-K-Ras drugs which include: altering K-
Ras nucleotide exchange, synthetic lethal interactors for essential mutant K-Ras genes, 
inhibiting components of K-Ras metabolic pathways, silencing K-Ras gene expression by 
RNA interference, inhibiting K-Ras downstream signaling effectors, and blocking K-Ras PM 
interaction (Cox, Fesik, Kimmelman, Luo, & Der, 2014; Papke & Der, 2017; W. Wang, Fang, 
& Rudolph, 2012) (Figure 6). Despite these efforts, there are still no approved anti-K-Ras 
drugs in clinical use.  
 
The first attempt to block K-Ras activity was to block Ras interaction with the PM by 
farnesyltransferase inhibitors (FTIs), which disrupts farnesylation, the first step of Ras 
post-translational modification and an essential step for the correct Ras post-translation 
modification (Cox et al., 2014). While early preclinical testing with FTIs showed promising  
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Ras cycles between an inactive Ras-GDP OFF state and active Ras-GTP ON state. 
Inactive Ras is activated by GEFs which promotes exchange of GDP for GTP. Active Ras 
is inactivated by GAPs, enhancing its intrinsic GTPase activity, and converts GTP to 
GDP. Ras-GTP mediates the activation of Ras downstream signaling pathways which 
are involved in various important cellular processes shown here. Figure adapted from 
(Spencer-Smith and O’Bryan, 2017). 
Figure 4. Ras signaling pathways 
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Wildtype Ras are predominately in a resting inactive Ras-GDP OFF state (left). 
Mutations at one of codons G12, G13 and Q61 disrupts the intrinsic GTPase activity of 
Ras, causing it to be insensitive to GAPs, and exists in a constitutively active Ras-GTP 
ON state (right). This promotes prolonged activation of downstream signaling effectors 
associated with cancer phenotypes. Figure adapted from (Spencer-Smith and O’Bryan, 
2017). 
 
Figure 5. Oncogenic mutant Ras is in a constitutively active state 
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responses in H-Ras-driven tumors, they were unsuccessful in inhibiting farnesylation in N-
Ras and K-Ras cells (Cox et al., 2014). When N-Ras and K-Ras cells were treated with FTIs, 
an alternative pathway in which geranylgeranyltransferase substitutes the required 
farnesyl with geranylgeranyl allows Ras to complete its post-translational modification, 
which results in normal Ras biological activity (Baines et al., 2011; Cox et al., 2014; Prior 
et al., 2012). However, despite the failure of FTIs in K-Ras cells, targeting K-Ras interaction 
with the PM still remains a valid therapeutic approach (Cho, van der Hoeven, et al., 2016; 
Cox, Der, & Philips, 2015; Zhou et al., 2017). 
 
Our lab focuses on K-Ras PM interaction since K-Ras must be localized to the PM for its 
full biological activity. We identified two molecular mechanisms that induce K-Ras 
dissociation from the PM and thereby reduce K-Ras signal output: 1) enhancing K-Ras 
phosphorylation (Bivona et al., 2006; Cho, Casteel, et al., 2016) and 2) reducing PS content 
from the PM (Cho et al., 2012; Cho, van der Hoeven, et al., 2016; Yeung et al., 2008). 
 
II. Natural-derived anti-cancer compounds 
A major challenge for anti-cancer drug development is to identify compounds that 
selectively inhibit the growth of cancer cells without affecting the health of normal cells 
in patients. With increased risk of adverse side effects, drug resistance emerging after 
prolonged treatment, and reduced efficacy of chemotherapeutic drugs, the use of 
chemotherapy is becoming more and more limited (Housman et al., 2014; Sak, 2012; 
Senapati, Mahanta, Kumar, & Maiti, 2018). In response to these challenges, there is a  
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Previous and current approaches for anti-K-Ras drug discovery include membrane 
association, direct binding, RNAi of K-Ras gene expression, synthetic lethal interactors, 
signaling inhibitors and cancer metabolism. Our lab focuses on disrupting K-Ras 
membrane association with the PM by two mechanisms: 1) enhancing K-Ras 
phosphorylation, and 2) reducing PS PM content. 
Figure 6. Approaches for anti-K-Ras drug discovery 
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growing interest in the development of combination therapies using naturally derived 
anti-cancer agents produced from plant, marine organism, and microbial sources as a new 
strategy to combat specific molecular pathways involved in cancer (Bayat Mokhtari et al., 
2017; Newman, Cragg, Holbeck, & Sausville, 2002). 
 
Plants have been extensively studied for many years and recently have garnered 
increased attention for extracting anti-cancer compounds, namely secondary 
metabolites, for their cost effectiveness, rich availability and low risk of adverse side 
effects (Desai et al., 2008; Greenwell & Rahman, 2015; H. Wang et al., 2012). Secondary 
metabolites are organic small molecules that possess chemical structures sufficient for 
synthetic synthesis, have unique cytotoxic effects in mammalian cells, and are efficiently 
produced in high concentrations in plants (Nascimento & Fett-Neto, 2010; Shitan, 2016). 
A. Triterpenoid saponins 
Saponins are a form of plant-derived secondary metabolites and are made up of 
hydrophobic aglycones, the non-sugar fragment of a glycoside (Moses, Papadopoulou, & 
Osbourn, 2014; X. H. Xu et al., 2016). They are classified, based on their aglycone (or 
sapogenin) structure, as triterpenoid saponins (five-ring) or steroidal saponins (four-ring) 
(Augustin, Kuzina, Andersen, & Bak, 2011; Moses et al., 2014) (Figure 7). Saponins employ 
several pharmacological effects including cardioprotective, anti-oxidant, anti-
inflammatory, immunoregulatory and anti-cancer properties (D. Singh & Chaudhuri, 
2018; X. H. Xu et al., 2016).  
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B. Avicin 
Avicin belong to a family of natural triterpenoid saponins derived from Acacia victoriae, a 
native Australian desert tree (Jayatilake et al., 2003). Avicin D and avicin G, the two most 
potent forms of avicin, are extracted from seedpod samples of A. victoriae and have been  
found to possess anti-inflammatory properties, activate anti-oxidant stress defense in 
mammalian cells, and anti-cancer characteristics which inhibit cancer cell growth in vitro 
(Haridas, Arntzen, & Gutterman, 2001; Mujoo et al., 2001; H. Wang, Haridas, Gutterman, 
& Xu, 2010) (Figure 8). Previous work revealed the anti-cancer effects of avicin by their 
ability to induce apoptosis in tumors by perturbing mitochondrial function, lowering 
energy metabolism, and inhibit activation of NF-κB (Haridas, Arntzen, et al., 2001; 
Haridas, Higuchi, et al., 2001; Haridas et al., 2007). However, the molecular mechanisms 
by which avicin prevent cancer growth and survival are still not fully understood. 
 
III. Hypothesis and Specific Aims 
 
Recently, our lab identified avicin, a family of plant-derived triterpenoid saponins, to have 
an effect on K-Ras localization at the PM.  Our preliminary experiments suggest avicin 
mislocalize K-Ras from the PM. 
 
We hypothesize that anti-cancer activity of avicin is through blocking K-Ras PM 
interaction and its biological activity. We will test our hypothesis in the following specific 
aims: 1) determine the effect of avicin on K-Ras PM interaction; 2) elucidate the molecular 
mechanism of action of avicin; and 3) characterize the role of avicin as an anti-K-Ras 
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cancer drug. The overall goal of this study is to identify the molecular mechanism of action 
by which avicin blocks oncogenic K-Ras activity. 
 
In our study, we identified that avicin G treatment mislocalizes K-Ras and PS from the PM 
through disruption of cellular sphingomyelin and ceramide balance. We observed a 
substantial increase in cellular sphingomyelin levels after avicin G treatment in addition 
to perturbation of sphingomyelinase activity and their cellular localization. Furthermore, 
avicin G treatment significantly reduced oncogenic Ras signaling and cell proliferation of 
K-Ras-dependent NCSLCs and PDACs, suggesting its anti-K-Ras activity. This study 
identifies avicin as a new potent sphingomyelinase inhibitor and suggests its role as an 
anti-K-Ras cancer drug.
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Representative sapogenin structures for triterpenoid (left) and steroidal (right) 
saponins. Figure adapted from (Augustin, Kuzina, et al., 2011). 
Figure 7. Sapogenins are the aglycone structures of saponins 
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Avicin D and avicin G are structurally similar triterpenoid saponins 
extracted from seedpod samples of A. victoriae. Avicin possess a core 5-
ring triterpenoid sapogenin structure and a side chain containing two 
units of acyclic monoterpenes. Avicin D (R=OH) and avicin G (R=H) differ 
at R- functional group (circled in red). Figure adapted from (Gutterman, 
Lai, et al., 2005; Haridas, Xu, et al., 2011). 
Figure 8. Chemical structures of avicin D and avicin G 
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MATERIALS AND METHODS 
I. Cell culture 
Madin-Darby canine kidney (MDCK) cells were maintained in Dulbecco’s modified eagle 
medium (DMEM, Cat#10569-010; Gibco) supplemented with 10% fetal bovine serum 
(FBS) (Cat#16000-044; Gibco), 2mM L-glutamine (Cat#CA009-010; GenDEPOT). Human 
non-small cell lung cancer cells (NSCLCs): H1299, H23, A549, H358, and H441 were all 
maintained in RPMI-1640 (Cat#30-2001; ATCC). Human pancreatic ductal 
adenocarcinoma cells (PDACs): BxPC3, AsPC-1 and Panc 10.05 were maintained in RPMI-
1640 (Cat#30-2001; ATCC), MiaPaCa-2 and PANC-1 were maintained in DMEM and HPAF-
II were maintained in EMEM (Cat#20-200; ATCC). All cancer cell lines were maintained in 
media supplemented with 10% FBS and 2mM L-glutamine. Cells were routinely tested for 
mycoplasma (Cat#LT07-710; MycoAlert PLUS Mycoplasma Detection Kit; Lonza; Rockland, 
ME). All cell lines were maintained in 37°C incubator with 5% CO2 injection. 
II. Antibodies 
The following antibodies used to measure Ras signaling were purchased from Cell 
Signaling Technology (Danvers, MA): pAkt (Ser473) (D9E) XP (Cat#4060), total Akt (pan) 
(40D4) (Cat#2920), p-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP (Cat#4370) 
and p44/42 MAPK (Erk1/2) (L34F12) (Cat#4696). The following antibodies used to 
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measure housekeeping genes were purchased from Proteintech (Rosemont, IL): GAPDH 
(Cat#60004-1-lg; clone #1E6D9), Beta actin (Cat#60008-1-1g) and GFP Tag (Cat#66002-1-
lg; clone #1E10H7).  
III. Organelle Markers  
CellLight™ Lysosomes-RFP BacMam 2.0 (Cat#C10597; Invitrogen™; Carlsbad, CA), which 
expresses RFP fused to LAMP1 (Lysosomal Associated Membrane Protein 1), was used for 
lysosome staining.  
IV. Avicin Compounds 
Avicin D and avicin G were provided in collaboration with Dr. Jordan Gutterman (MD 
Anderson Cancer Center; Houston, TX). 
V. Ras and PS PM Localization 
MDCK cells stably co-expressing mGFP-K-Ras4BG12V, -K-HasG12V, -K-Ras4AG12V, -K-
RasG12V AAA (S17A, S181A, T183A), or -LactC2 (a PS marker) with mCherry-CAAX (a 
general endomembrane marker) were grown to super confluency and passaged at a 1:20 
dilution. Cells were washed 2x with 1X phosphate saline buffer (PBS) and complete 
growth media (DMEM) was replaced after every two days. 
A. Cell Seeding 
On day one, when MDCK cells were super confluent, adherent cells were detached by 
addition of 2mL of 0.25% trypsin (Cat#25200-072; Gibco) and incubated in 37°C for several 
minutes. Trypsinized cells were then quenched in an equal 2mL volume of complete 
growth media and mixed. Suspended cells were then diluted 1:7 in complete growth 
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media and counted using Countess II Automated Cell Counter (Life Technologies; Thermo 
Fisher Scientific; Rockford, IL). 1.75, 2.0, 2.25, 2.5 or 2.75 x 105 cells were seeded to 12-
well plate containing 2mL of complete growth media and glass coverslips. Seeded cells 
were then placed into 37°C incubator for 24h. 
B. Drug Treatment and Fixing Cells 
On day two after 24h from seeding, MDCK cells were treated with DMSO (control) or 
various concentrations of avicin D or avicin G (5, 10, 50, 100, 500, 1000nM) at 15-20% cell 
confluency. On day three, cells were approximately 60-70% confluent. On day four, cells 
were super confluent and fixed with 4% paraformaldehyde (PFA) (Cat#15710; Electron 
Microscopy Sciences; Hatfield, PA) in dark for 30 min. Fixed cells were quenched with 
NH4Cl (50mM) in dark for 10 min. Coverslips were mounted to glass microscope slides 
using mowiol or Vectashield (Cat#H-1000; Vector Laboratories; Burlingame, CA) mounting 
medium and dried at 4°C. On day five, images were taken using a confocal microscope.  
VI. Sphingomyelinase Localization 
MDCK cells stably expressing SMPD1-, SMPD2- or SMPD3-mGFP were grown to super 
confluency and passaged at a 1:20 dilution. Cells were washed 2x with 1X PBS and 
complete growth media was replaced after every two days. 
On day one 3.0 x 105 cells were seeded, on day two cells were treated with avicin G 
(500nM) for 48h, on day four cells were fixed with 4% PFA and on day five cells were 
imaged with a confocal microscope as described in V. Ras and PS PM localization.  
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VII. Lipid Add-back (Exogenous Ceramide) 
MDCK cells stably co-expressing mGFP-K-RasG12V or mGFP-LactC2 with mCherry-CAAX (a 
general endomembrane marker) were grown to super confluency and passaged at a 1:20 
dilution. Cells were washed 2x with 1X PBS and complete growth media was replaced 
after every two days. 
A. Cell Seeding and Drug Treatment 
On day one 2.75 x 105 cells were seeded to 5x 12-well plates (for time points T=15, 30, 60, 
120min) and on day two treated with avicin G (500nM) for 48h as described in V. Ras and 
PS PM localization.  
B. Ceramide (Cer) Preparation 
On day three, 5.3µL of Cer stock (13.154mM) (Cat#860052; Avanti Polar Lipids; Alabaster, 
AL) was transferred using a Hamilton syringe into an amber glass vial and placed in a 
vacuum desiccation chamber overnight at room temperature in dark to dry the lipid. 
C. Cer Add-back and Fixing Cells 
On day four, 2mL of serum free media was added to the dried Cer and sonicated for 1h in 
a water bath sonicator. 2mL of Cer suspension was transferred to 5mL of complete growth 
media for a final concentration of 10µM. Final volume of Cer (10µM) was split to two 
15mL tubes and DMSO (control) or avicin G (500nM) was added to each aliquot and mixed 
to solution. MDCK cells treated with DMSO (control) or avicin G (500nM) at super 
confluency were washed 2x with ice-cold 1X Hanks’ balanced salt buffer (HBSS) and 
incubated with 1X HBSS for 15min on ice in cold room. Cells were then washed 2x with 1x 
HBSS and further incubated with 0.5mL of Cer (10µM) containing DMSO (control) or avicin 
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G (500nM) for 10min on ice. After the incubation, T=15, 30, 60, 120 min cells were 
returned to 37°C incubator, and T=0 cells were then fixed with 4% PFA in dark for 1h in 
cold room. Cells were then transferred to room temperature where they were quenched 
in NH4Cl (50mM) in dark for 10 min. Coverslips were mounted to glass microscope slides 
using mowiol or Vectashield (Cat#H-1000; Vector Laboratories; Burlingame, CA) mounting 
medium and dried at 4°C. T=15, 30, 60, 120min cells were fixed at appropriate time points 
just as T=0. Images were taken using a confocal microscope. 
VIII. Western Blot Analysis 
MDCK cells stably expressing mGFP-K-RasG12V and -H-RasG12V or SMPD1-, SMPD2-, 
SMPD3-mGFP were grown to super confluency and passaged at a 1:20 dilution. Cells were 
washed 2x with 1X PBS and complete growth media was replaced after every two days. 
A. Cell Seeding 
On day one 3.5 x 105 cells were seeded to 6-well plate and on day two treated with treated 
with DMSO (control) or various concentrations of avicin G (5, 10, 100, 500, 1000nM) for 
48h as described in V. Ras and PS PM localization.  
B. Harvesting Whole Cell Lysates 
On day four after 48h of drug treatment, cells were super confluent and washed 2x with 
1X PBS. Appropriate amounts of lysis buffer B (50mM Tris, pH 7.5, 75mM NaCl, 25mM 
NaF, 5mM MgCl2, 5mM EGTA, 3.3µg/µL aprotinin, 0.1mM Na3VO4, 0.1mg/mL, leupeptin, 
1mM DTT, 1% NP-40) was applied to each well and cells were scraped using cell scraper 
tool to remove adhered cells from the well surface. Whole cell lysates were then 
transferred to 1.5mL tubes, mixed well, and incubated on ice for 5 min. Mixing and 
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incubation in ice were repeated twice, followed by centrifugation at 15,000 rpm for 10 
min at 4°C. Supernatant were transferred to chilled 1.5mL tubes and stored in -80°C until 
further use. 
C. Preparing Samples 
Whole cell lysate protein concentrations were measured by BCA protein assay (Reagent 
A Cat#PI23221/PI23223, Reagent B Cat# PI23224; Thermo Fisher Scientific; Rockford, IL). 
Samples for SDS-PAGE were prepared containing 20µg of protein and denatured at 95°C 
for 5 min.  
D. SDS-PAGE and PVDF Membrane Transfer 
SDS-PAGE gels were prepared at various polyacrylamide percentages based on the 
expected molecular weight of protein of interest. Denatured protein samples were loaded 
to SDS-PAGE gel and run at 80V for 15min and 120V for 1.5h (1h 45min total). Gels were 
then transferred to PVDF membranes (Cat# 1620177; Bio-Rad; Hercules, CA) using a semi-
dry transfer system (Trans-Blot SD Semi-Dry Transfer Cell; Bio-Rad; Hercules, CA) at 15V 
for 30 min per membrane. PVDF membranes were incubated in blocking buffer at room 
temperature for 1h to prevent non-specific binding. 5% bovine serum albumin (BSA) in 
TBST (10mM Tris, pH 7.5, 150mM NaCl, 0.1% Tween-20) was used for phospho-proteins 
and 5% dry non-fat milk in TBST was used for non-phospho-proteins. PVDF membranes 
were then incubated overnight at 4°C in blocking buffer containing primary antibody. The 
following dilutions were used for primary antibodies: GFP (1:4,000), ppERK (1:4,000), 
pAKT (1:1,000), total ERK (1:1,000), total AKT (1:2,000), GAPDH (1:8,000), beta actin 
(1:5,000). 
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The next day, PVDF membranes were washed 3x with 1X TBST and incubated in blocking 
buffer containing secondary antibody at room temperature for 1h. Mouse (goat anti-
mouse IgG (H+L) horseradish peroxidase (HRP) conjugate; Cat#G21040; Invitrogen™; 
Carlsbad, CA) and rabbit (goat anti-rabbit IgG (H+L) HRP conjugate; Cat#G21234; 
Invitrogen™; Carlsbad, CA) secondary antibodies were used for appropriate primary 
antibody conjugation. The following dilutions were used for secondary antibodies: mouse 
(1:2,000) and rabbit (1:5,000). The membranes were developed with Super Signal West 
Pico Plus Chemiluminescent Substrate (Cat#34578; Thermo Fisher Scientific; Rockford, IL) 
with the addition of Super Signal West Dura Extended Duration Substrate (Cat#34076; 
Thermo Fisher Scientific; Rockford, IL) as necessary (4:1 dilution). Western blots were 
developed using an Amersham Imager 600 (GE Healthcare Life Sciences; Marlborough, 
MA). 
E. Analysis 
ImageJ software (ver. 1.52a) was used to perform densitometric analysis of developed 
protein bands on PVDF membranes. Each lane was normalized to control (DMSO-treated) 
and further statistical calculations were performed in GraphPad Prism (ver. 5.0c). 
IX. Sphingomyelinase Activity Assay 
Amplex™ Red Sphingomyelinase Assay Kit (Cat#A12220; Invitrogen™; Carlsbad, CA) was 
used to measure endogenous sphingomyelinase activity after addition of exogenous 
sphingomyelin (SM). All reagents were prepared according to manufacturer’s 
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instructions. Whole cell lysates were prepared as described in VIII.b. Western blot: 
Harvesting Whole Cell Lysates (without DTT). 
 
There are two steps to the Sphingomyelinase Activity Assay which measure 1) neutral 
sphingomyelinase under neutral conditions (pH 7.4) and 2) acid sphingomyelinase under 
acidic conditions (pH 5.0). 
A. Neutral Sphingomyelinase Assay (pH 7.4) 
33µg of whole cell lysates of MDCK cells stably expressing mGFP-K-RasG12V treated with 
DMSO (control) or various concentrations of avicin G (5, 10, 100, 500, 1000nM) for 48h 
were prepared to a volume of 35µL with lysis buffer B (without DTT). 130µL 1x reaction 
buffer (0.5 M Tris-HCl, 50 mM MgCl2, pH 7.4) was added to the sample to have a final 
protein concentration of 0.2µg/µL. 0.1 U/mL sphingomyelinase and 1X reaction buffer 
were used as a positive and a negative control, respectively. A black microplate was used 
to load 50µL of samples and controls in triplicate wells, followed by addition of an equal 
50µL volume of Amplex Red reaction mixture (100 µM Amplex Red reagent, 2 U/mL 
horseradish peroxidase, 0.2 U/mL choline oxidase, 8 U/mL alkaline phosphatase, 0.5 mM 
SM). The plate was incubated in dark in 37°C for 30 min and endogenous 
sphingomyelinase activity was measured using BioTek Synergy H1 microplate reader 
(excitation λ = 540 nm, emission λ = 590 nm). The plate was returned to 37°C for an 
additional 30 min incubation (1h total) and measured again. 
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B. Acid Sphingomyelinase Assay (pH 5.0) 
33µg of whole cell lysates of MDCK cells stably expressing mGFP-K-RasG12V treated with 
DMSO (control) or various concentrations of avicin G (5, 10, 100, 500, 1000nM) for 48h 
were prepared to a volume of 35µL with lysis buffer B (without DTT). 130µL low pH buffer 
(50 mM sodium acetate, pH 5.0) was added to the sample to have a final protein 
concentration of 0.2µg/µL. 0.1 U/mL sphingomyelinase and low pH buffer were used as a 
positive and negative control, respectively. A black microplate was used to load 50µL of 
samples and the negative control in triplicate wells, followed by addition of 5µL of SM 
(5mM). The plate was incubated in dark in 37°C for 1h. 50µL of positive control (0.1 U/mL 
sphingomyelinase) was loaded in triplicate wells to the plate. The pH was then raised to 
7.0 – 8.0 with the addition of an equal 50µL volume of Amplex Red reaction mixture (100 
µM Amplex Red reagent, 2 U/mL horseradish peroxidase, 0.2 U/mL choline oxidase, 8 
U/mL alkaline phosphatase) containing high pH buffer (100 mM Tris-HCl, pH 8.0) to each 
sample and controls. The plate was incubated in dark in 37°C for 30 min and 
sphingomyelinase activity was measured using BioTek Synergy H1 microplate reader 
(excitation λ = 540 nm, emission λ = 590 nm). The plate was returned to 37°C for an 
additional 30 min incubation (1h total) and measured again. 
X. Proliferation Assay 
NSCLCs (H1299, H23, A549, H358, H441) and PDACs (BxPC3, AsPC-1, Panc10.05, MiaPaCa-
2, HPAF-II, PANC-1) were grown to 80-90% confluency and passaged at a 1:20 dilution. 
Cells were washed 2x with 1X PBS and appropriate growth media was replaced after every 
two days. 
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A. Cell Seeding 
When NSCLCs or PDACs were >80% confluent, adherent cells were detached using 0.05% 
trypsin (Cat#25300-062; Gibco) and counted as described in V. Ras and PS PM 
localization. 1 x 104 cells were seeded in 100µL complete growth media per well on a 96-
well plate. Cells were incubated at 37°C with 5% CO2 for 24h. 
B. Drug Treatment  
NSCLCs or PDACs were treated with DMSO (control) or various concentrations of avicin G 
(500, 1000, 1250, 1500 nM) every 24h for 3 days. On the last day, media was aspirated to 
waste and 100µL of 1X dye binding solution (CyQUANT NF Cell Proliferation Assay Kit; 
Cat#C35006; Molecular Probes; Eugene, OR) was applied to each well and the plate was 
incubated in dark in 37°C. Fluorescence intensity was measured using BioTek Synergy H1 
microplate reader (excitation λ = 480 nm, emission λ = 530 nm) every 15 min from T=15 
min to T = 75 min.  
XI. mGFP-Lysenin Purification 
BL21 was transformed with MBP-mGFP-Lysenin construct, a kind gift from Dr. Greg Fairn 
(University of Toronto), and cultured in LB medium at 37°C. When optical density at 560 
nm (OD560) reached 0.5, 5mL of IPTG (100mM) was added and further incubated at 25°C 
for 5 hours with shaking. Cells were sedimented by centrifugation at 10,000 rpm for 10 
min at 4°C. Bacterial pellet was collected and lysis buffer (1.25µg/mL PMSF, 50ng/mL 
aprotinin, 50ng/mL leupeptin, 20U/µL DNaseI, 0.5mg/mL Lysozyme) was added and 
sonicated for 1h at 4°C. After sonication, 1% Triton X-100 was added and mixed for 30min 
at 4°C. Cells were sedimented at 10,000 rpm for 10min at 4°C. Bacterial cell lysate was 
 
 
28 
collected and bound to amylose resin (Cat#E8021S; New England BioLabs) overnight at 
4°C. The resin was washed with 12 column volumes of column buffer (20mM Tris-HCl pH 
7.4, 200mM Sodium Chloride, 1mM EDTA) and packed into a column. MBP-mGFP-Lysenin 
was eluted from the resin with 100mL of elution buffer (column buffer containing 10mM 
Maltose) and 5mL fractions were collected. 
XII. mGFP-Lysenin Staining 
Wild-type (WT) MDCK cells were grown to super confluency and passaged at a 1:20 
dilution. Cells were washed 2x with 1X PBS and complete growth media was replaced 
after every two days. 
A. Cell Seeding and Drug treatment 
2.75 x 105 cells were seeded to 12-well plate containing complete growth media and glass 
coverslip as described in V. Ras and PS PM localization. Cells were treated with DMSO 
(control) or avicin G (500nM) as described in V. Ras and PS PM localization. 
B. Cell Permeabilization and mGFP-Lysenin Labeling 
WT MDCK cells treated with DMSO (control) or avicin G (500nM) were either 
permeabilized (treated with 0.05% saponin) with mGFP-Lysenin or non-permeabilized 
(untreated with 0.05% saponin) for mGFP-Lysenin binding to exofacial leaflets of the PM.  
i. Intracellular SM Labeling 
MDCK WT cells treated with DMSO (control) or avicin G (500nM) for 48h were fixed in 
dark for 30 min with 4% PFA. Fixed cells were permeabilized with 0.05% saponin for 30 
min at room temperature and further labeled with mGFP-Lysenin (15µg) for 15 min at 
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room temperature. Cells were then quenched with NH4Cl (50mM) in dark for 10 min, and 
further labeled with DAPI (5mg/mL) in dark for 10 min. Coverslips were mounted to glass 
microscope slides using mowiol mounting medium and dried at 4°C. Images were taken 
using a confocal microscope. 
ii. mGFP-Lysenin Binding to Exofacial Leaflets of the PM 
WT MDCK cells treated with DMSO (control) or avicin G (500nM) for 48h were labeled 
with mGFP-Lysenin (15µg) for 15 min at room temperature. mGFP-Lysenin labeled cells 
were fixed in dark for 30 min with 4% PFA and were further quenched with NH4Cl (50mM) 
in dark for 10 min. Cells were then labeled with DAPI (5mg/mL) in dark for 10 min. 
Coverslips were mounted to glass microscope slides using mowiol mounting medium and 
dried at 4°C. Images were taken using a confocal microscope. 
XIII. Confocal Imaging 
All fluorescent images were captured using an Olympus FLUOVIEW FV1000 confocal laser 
scanning biological microscope (Olympus Life Science Solutions). 
XIV. Manders Coefficient Quantitation 
Co-localization of mGFP-tagged and mCherry-tagged proteins were measured using 
Manders coefficient calculation in ImageJ software (ver. 1.52a). 
XV. Statistical Analysis 
All statistical analysis (Student’s t-test and One-way ANOVA) were calculated using 
GraphPad Prism (ver. 5.0c). 
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RESULTS 
I. Determine the effect of avicin on K-Ras plasma membrane interaction 
A. Manders coefficient 
To determine the effects of avicin on K-Ras interaction at the PM, we utilized Manders 
coefficient analysis, a tool used to measure the co-localization of two fluorophores, to 
quantify the degree of co-localization between mGFP-tagged proteins with mCherry-
tagged proteins via ImageJ software (ver. 1.52a) (Manders, Verbeek, & Aten, 1993) For 
example, MDCK cells stably expressing mGFP-K-RasG12V with mCherry-CAAX, an general 
endomembrane marker (Choy et al., 1999) were treated with DMSO (control) or 
oligomycin A (a mitochondrial inhibitor) for 48h. Cells were fixed with 4% PFA and imaged 
using a confocal microscope.  Manders coefficient values were calculated for each 
treatment condition (Cho, Casteel, et al., 2016) (Figure 9). Manders coefficient values are 
calculated by the number of red pixels co-localized with green pixels divided by the total 
number of red pixels. Therefore, a low Manders coefficient value represents less co-
localization, whereas a high Manders coefficient value represents greater co-localization. 
This suggests that after oligomycin A treatment which mislocalizes K-Ras from the PM 
through phosphorylating K-Ras Ser181 residue (Cho, Casteel, et al., 2016), a higher 
Manders coefficient value (0.75) represents a larger degree of K-Ras mislocalization from  
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the PM compared to the lower Manders coefficient value (0.33) of DMSO (control) 
treated cells. 
B. Avicin effect on K-Ras PM interaction 
i. Avicin mislocalizes K-Ras from the PM 
MDCK cells stably co-expressing mGFP-K-RasG12V with mCherry-CAAX were treated with 
DMSO (control) or avicin D and avicin G for 48h (Figure 10). Cells were fixed with 4% PFA 
and imaged with a confocal microscope. We found that avicin treatment mislocalizes K-
RasG12V at low concentrations (100nM) and at higher concentrations (>500nM) K-
RasG12V accumulates to intracellular vesicles (Figure 10A). Manders coefficient values 
were used to calculate IC50 values for avicin D (142.2nM) and avicin G (73.8nM), which 
suggest avicin D and avicin G treatments mislocalize K-RasG12V from the PM at different 
efficacies (Figure 10B). This data shows that avicin G is more potent at mislocalizing K-Ras 
from the PM. For this reason, we focused on investigating the effect of avicin G on K-Ras 
PM interactions for all experiments moving forward. 
ii. Avicin G translocates K-Ras to lysosomes and other endomembranes 
In order to investigate the accumulation of intracellular vesicles upon avicin G treatment 
at higher concentrations (>500nM), avicin G-treated MDCK cells stably expressing mGFP-
K-RasG12V were infected with baculovirus expressing mRFP-tagged different organelle 
markers to identify where K-RasG12V is mislocalized to from the PM. We found that K-
RasG12V co-localized with a lysosomal marker, mRFP-LAMP1, at low concentrations 
(100nM), suggesting K-Ras translocation to the lysosome in avicin G-treated cells (Figure 
11). In addition, we found that avicin G treatment at higher concentrations (>500nM) 
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MDCK cells stably co-expressing mGFP-K-RasG12V with mCherry-
CAAX were treated with oligomycin A (a mitochondrial inhibitor) 
for 48h. Cells were fixed with 4% PFA and imaged with a confocal 
microscope. Manders coefficient values were calculated in ImageJ 
software (ver. 1.52a) to measure for co-localization of mGFP-K-
RasG12V with mCherry-CAAX Figure adapted from (Cho, Casteel, 
et al., 2016). 
Figure 9. Manders coefficient 
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(A) MDCK cells stably co-expressing GFP-K-RasG12V with mCherry-CAAX were 
treated with DMSO (control) and avicin D (top) or avicin G (bottom) for 48h. Cells 
were fixed with 4% PFA and imaged with a confocal microscope. Manders 
coefficient values were calculated in ImageJ software (ver. 1.52a) to measure for 
co-localization of mGFP-K-RasG12V with mCherry-CAAX. (B) The graphs show 
mean +/- S.E.M. of Manders coefficients, which were used to calculate IC50 values 
for avicin D (142.2nM) and avicin G (73.8nM) from three independent 
experiments. One-way ANOVA test was performed to determine the significant 
differences (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, N.S. – not 
significant) between DMSO (control) treated and avicin treated cells. 
Figure 10. Avicin D and avicin G mislocalize K-RasG12V from the PM 
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MDCK cells stably expressing GFP-K-RasG12V were treated with DMSO (control) or 
avicin G for 48h. During the treatment, cells were incubated with baculovirus 
expressing mRFP-LAMP1, a lysosomal marker, for the last 16h, and fixed with 4% PFA 
and imaged with a confocal microscope. The arrows indicate K-RasG12V 
translocation to lysosomes or other endomembranes. 
 
Figure 11. Avicin G translocate K-Ras to lysosomes and other endomembranes 
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resulted in K-RasG12V translocated to lysosomes as well as endomembranes (Figure 11). 
Taken together, avicin G mislocalizes K-Ras from the PM to lysosomes and other 
endomembranes. 
iii. Avicin G is K-Ras-specific 
Next, in order to determine whether avicin G is K-Ras-specific, we tested avicin G 
treatment on cell lines expressing other Ras isoforms. MDCK cells stably co-expressing 
mGFP-H-RasG12V or -K-Ras4AG12V, the alternate splice variant of K-Ras, with mCherry-
CAAX were treated with DMSO (control) or avicin G for 48h (Figure 12A). Cells were fixed 
with 4% PFA and imaged with a confocal microscope. We calculated Manders coefficient 
values for DMSO (control) treated and avicin G treated cells and found that avicin G 
treatment had low or no effect on both mGFP-H-RasG12V and mGFP-K-Ras4AG12V 
localization at the PM (Figure 12B). Taken together, this data suggests that avicin G is 
specific to K-Ras but not with other Ras isoforms. 
 
II. Elucidate the molecular mechanism of action of avicin 
A. Mislocalizing K-Ras from the PM 
i. Avicin-mediated K-Ras mislocalization from the PM is phosphorylation-
independent 
K-Ras localization at the PM is maintained via intracellular trafficking to and from recycling 
endosomes, which act as a post-Golgi exocytic pathway to the PM (Misaki et al., 2010). 
Recent studies found that K-Ras phosphorylation at Serine 181 alters its endocytic 
recycling and leads to its mislocalization from the PM (Cho, Casteel, et al., 2016).  
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(A) MDCK cells stably co-expressing mGFP-H-RasG12V or -K-
Ras4AG12V with mCherry-CAAX were treated with DMSO (control) 
or avicin G for 48h. Cells were fixed with 4% PFA and imaged using a 
confocal microscope. (B) Manders coefficient values were calculated 
to measure Ras mislocalization from the PM after avicin G 
treatment. 
 
Figure 12. Avicin G is K-Ras-specific 
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Therefore, enhancing K-Ras phosphorylation is one approach to target K-Ras interaction 
at the PM and block its activity.  
 
To elucidate the mechanism of action of avicin compounds on K-Ras PM localization, we 
first determined whether avicin G treatment had an effect on K-Ras-phosphorylation. We 
generated a mutant MDCK cell line stably co-expressing mCherry-CAAX with mGFP-K-
RasG12V AAA mutant insensitive to phosphorylation, where putative K-Ras 
phosphorylation residues Serine 171, Serine 181, and Threonine 183 were point-mutated 
to alanine. MDCK cells stably co-expressing mGFP-K-RasG12V AAA with mCherry-CAAX 
were treated with DMSO (control) or avicin G for 48h (Figure 13A). Cells were fixed with 
4% PFA and imaged with a confocal microscope. Manders coefficient values were used to 
calculate the IC50 value (74.7 nM) (Figure 13B). We found that with avicin G treatment, 
mGFP-K-RasG12V AAA is dose-dependently mislocalized from the PM. Taken together, 
our data shows that avicin-mediated K-Ras mislocalization from the PM is 
phosphorylation-independent. 
ii. Avicin G redistributes PS from the PM 
Another approach to target K-Ras localization to the PM is through disrupting cellular PS 
content and trafficking at the PM. It is known that the K-Ras polybasic domain in its 
hypervariable region electrostatically interacts with the negatively charged phospho-
head group of PS at the inner leaflet of the PM (Cho, van der Hoeven, et al., 2016; Yeung 
et al., 2008) Previous studies have shown that redistributing PS from the PM results in K- 
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(A) MDCK cells stably expressing mGFP-K-RasG12V AAA (S171A, S181A, T183A) with 
mCherry-CAAX were treated with DMSO (control) or avicin G for 48h. Cells were 
fixed with 4% PFA and imaged using a confocal microscope. (B) Manders coefficient 
values were used to calculate an IC50 value (74.7nM) and measure for mislocalization 
from the PM. The graph shows mean +/- S.E.M of Manders coefficient values after 
avicin G treatment from three independent experiments. One-way ANOVA test was 
performed to determine the significant differences (*** p<0.001, N.S. – not 
significant) between DMSO (control) treated and avicin G treated cells. 
Figure 13. Avicin-mediated K-Ras mislocalization from the PM is phosphorylation-
independent 
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Ras mislocalization from the PM (Cho et al., 2012; Cho, van der Hoeven, et al., 2016; Yeung 
et al., 2008). 
 
Next, we further looked into the mechanism of avicin compounds by testing the cellular 
localization of mGFP-LactC2, a well-known PS marker (Cho et al., 2012; Cho et al., 2015; 
Yeung et al., 2008). MDCK cells stably co-expressing mGFP-LactC2 with mCherry-CAAX 
were treated with DMSO (control) or avicin G for 48h (Figure 14A). Cells were fixed with 
4% PFA and imaged with a confocal microscope. Manders coefficient values were used to 
calculate the IC50 value (69.7 nM) (Figure 14B). We found that with avicin G treatment, 
mGFP-LactC2 is dose-dependently mislocalized from the PM. Taken together, our data 
shows that avicin-mediated mGFP-LactC2 mislocalization from the PM suggests avicin G 
redistributes PS from the PM.  
B. Disrupting cellular sphingomyelin/ceramide (SM/Cer) balance 
Sphingomyelin (SM) and ceramide (Cer) are bioactive sphingolipids involved in a variety 
of important cellular functions and are essential components to cellular membranes, 
including the PM (Zheng et al., 2006). Previous studies suggest that regulation of cellular 
SM and Cer balance by sphingomyelinases is important for K-Ras and PS localization at 
the PM (Cho, van der Hoeven, et al., 2016; van der Hoeven et al., 2018). 
Sphingomyelinases (SMases) catalyze the hydrolysis of SM to Cer and choline, and 
inhibition of SMases results in disrupting SM and Cer balance (Cho, van der Hoeven, et 
al., 2016; van der Hoeven et al., 2018). A recent study showed that fendiline, a potent  
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MDCK cells stably co-expressing mGFP-LactC2 with mCherry-CAAX were treated 
with DMSO (control) or avicin G for 48h. Cells were fixed with 4% PFA and 
imaged with a confocal microscope. Manders coefficient values were used to 
calculate an IC50 value (69.7nM) and measure for mislocalization from the PM. 
The graph shows mean +/- S.E.M of manders coefficient values after avicin G 
treatment from three independent experiments. (** p<0.01, *** p<0.001, **** 
p<0.0001, N.S. – not significant) between DMSO (control) treated and avicin G 
treated cells. 
Figure 14. Avicin G redistributes PS from the PM 
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acid sphingomyelinase (A-SMase) inhibitor, mislocalizes K-Ras and PS from the PM (Cho, 
van der Hoeven, et al., 2016). Furthermore, oncogenic K-Ras or LactC2 expressing cells 
treated with additional acid sphingomyelinase inhibitors (tricyclic anti-depressants: 
imipramine, desipramine, and amitriptyline), also mislocalizes K-Ras and PS from the PM 
(van der Hoeven et al., 2018). Therefore, altering cellular SM and Cer balance through 
sphingomyelinase inhibition is a potential approach to targeting K-Ras and PS localization 
at the PM. 
i. Avicin G elevates cellular SM content and disrupts SM distribution 
In the aforementioned studies, upon acid sphingomyelinase inhibition, MDCK cells stably 
expressing mGFP-K-RasG12V were measured for lipid content, which showed increased 
SM and decreased Cer levels (Cho, van der Hoeven, et al., 2016; van der Hoeven et al., 
2018). These studies also found that SM cellular distribution was altered after acid 
sphingomyelinase inhibition (Cho, van der Hoeven, et al., 2016; van der Hoeven et al., 
2018). Taken together, lipid content and distribution of SM and Cer after acid 
sphingomyelinase inhibition resulted in altered cellular lipid levels. 
 
Furthermore, we tested the cellular content and distribution of SM after avicin G 
treatment (Figure 15). We performed lipidomic analysis in whole cell lysates of MDCK cells 
stably expressing mGFP-K-RasG12V treated with DMSO (control) or avicin G and found 
elevated levels of SM (Figure 15A). We further treated wild-type MDCK cells with avicin G 
for 48h, permeabilized with 0.05% saponin and co-stained with recombinant mGFP-
Lysenin, an SM probe, and DAPI. Cells were fixed with 4% PFA and imaged with a confocal  
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(A) MDCK cells stably expressing mGFP-K-RasG12V were 
treated with DMSO (control) or avicin G (250nM) and 
whole cell lipidomics for SM was measured. The graph 
shows mean +/- S.E.M of totsl SM levels. (B) Wild-type 
MDCK (WT) cells treated with DMSO (control) or avicin 
G (500nM) for 48h were permeablized with 0.05% 
saponin and co-stained with mGFP-Lysenin (SM) and 
DAPI. Cells were fixed with 4% PFA and imaged with a 
confocal microscope. 
Figure 15. Avicin G elevates cellular SM content and 
disrupts SM distribution 
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microscope. Our data shows minimal mGFP-Lysenin staining in DMSO (control) treated 
cells and a substantial accumulation of mGFP-Lysenin in avicin G-treated cells (Figure. 
15B). These data that avicin G treatment accumulates SM to intracellular vesicles. Taken 
together, our data indicate that avicin G elevates cellular SM content and disrupts SM 
distribution. 
C. Inhibiting sphingomyelinases (SMases) 
Next, we determined the effect of avicin G on sphingomyelinases. There are two types of 
sphingomyelinases, acid (SMPD1) sphingomyelinase (A-SMase) and neutral (SMPD2 and 
SMPD3) sphingomyelinase (N-SMase). As stated earlier, inhibiting acid sphingomyelinases 
disrupted cellular SM and Cer balance, which led to K-Ras and PS mislocalization from the 
PM (Cho, van der Hoeven, et al., 2016). We showed that avicin G mislocalizes K-Ras and 
PS from the PM (Figures 10A and 14). Therefore, to test whether avicin G disrupts SM and 
Cer balance by inhibiting sphingomyelinases, we first looked at the effects of avicin G on 
sphingomyelinase activity. 
i. Avicin G disrupts SMase activity 
We first determined the effect of avicin G on sphingomyelinase activity using Amplex™ 
Red Sphingomyelinase Assay Kit (Cat#A12220; Invitrogen; Carlsbad, CA). MDCK cells 
stably expressing mGFP-K-RasG12V were treated with DMSO (control) or avicin G for 48h. 
Samples were supplemented with exogenous sphingomyelinase and measured for 
endogenous sphingomyelinase activity in neutral (pH 7.4) or acidic (pH 5.0) buffered 
conditions. Our data shows that in neutral (pH 7.0) conditions, avicin G was more potent 
at reducing sphingomyelinase activity at low concentrations (<100nM), whereas in acidic  
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MDCK cells stably expressing mGFP-K-RasG12V were treated with DMSO 
(control) or avicin G for 48h. Whole cell lysates were harvested and 
measured for endogenous SMase activity. The assay was performed in 
neutral (pH 7.4) or acidic (pH 5.0) environments to measure activities of 
neutral or acid SMases, respectively. The graph shows the mean +/- S.E.M. 
relative SMase activities after avicin G treatment from four independent 
experiments. (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, N.S. – 
not significant) between DMSO (control) treated and avicin G treated 
cells. 
 
Figure 16. Avicin G disrupts SMase activity 
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(pH 5.0) conditions, avicin G was more effective at reducing sphingomyelinase activity at 
higher concentrations (>500nM) (Figure 16). Taken together, this data suggests that avicin 
G preferentially inhibits the activity of N-SMase over A-SMase.  
ii. Avicin G disrupts SMase cellular localization 
To further determine the effect of avicin G on sphingomyelinase activity, we generated 
several MDCK cells stably expressing SMPD1- SMPD2- or SMPD3-mGFP and treated with 
DMSO (control) or avicin G for 48h. Cells were fixed with 4% PFA and imaged with a 
confocal microscope. Our data show that lysosomal localization in SMPD1-mGFP (A-
SMase) control cells was disrupted in avicin G -treated cells, whereas SMPD2-mGFP (N-
SMase) was accumulated to intracellular vesicles in avicin G treated cells (Figure 17). 
Cellular localization in SMPD3-mGFP (N-SMase) was not disrupted in avicin-treated cells 
(Figure 17). Taken together, avicin G treatment disrupts both SMPD2 and SMPD1 cellular 
localization. 
iii. Avicin G disrupts SMase protein expression level 
Furthermore, we determined the effect of avicin G on sphingomyelinase protein 
expression level. MDCK cells stably expressing SMPD1-, SMPD2- or SMPD3-mGFP were 
treated with DMSO (control) or avicin G for 48h. Whole cell lysates were harvested, and 
western blot analysis was performed against anti-GFP antibody to detect total SMase 
protein expression level. Our data show that avicin G treatment significantly reduced 
SMPD1-mGFP at high concentration (>500nM), whereas it dose-dependently increased 
SMPD2-mGFP protein levels (Figure 18). Protein expression in SMPD3-mGFP cells was not 
significantly changed after avicin G treatment (Figure 18). Taken together, avicin G  
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MDCK cells stably expressing SMPD1-, SMPD2- or SMPD3-GFP were treated with 
DMSO (control) or avicin G (500nM) for 48h. Cells were fixed with 4% PFA and 
imaged with a confocal microscope. Arrowheads indicate SMase localization to 
intracellular vesicles. 
 
Figure 17. Avicin G disrupts SMase cellular localization 
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MDCK cells expressing SMPD1-, SMPD2- 
or SMPD3-mGFP were treated with DMSO 
(control) or avicin G for 48h. Whole cell 
lysates were harvested, and western blot 
analysis was performed against anti-GFP 
antibody to detect total SMase protein 
expression level. (A) Representative blots 
are shown with actin used as loading 
controls. (B) Densitometric analysis shows 
the mean +/- S.E.M. of relative SMPD 
expression levels from three independent 
experiments. (* p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001, N.S. – not 
significant). 
Figure 18. Avicin G disrupts SMase 
protein expression level 
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treatment starts to increase SMPD2 expression level at a lower concentration in a dose-
dependent manner, whereas the treatment decreases SMPD1 expression level only at 
higher concentrations. 
D. Supplementation with exogenous Cer 
We showed that avicin G treatment mislocalizes K-Ras and LactC2 from the PM. To 
elucidate this mechanism, we found that avicin G increases cellular SM level, and disrupts 
A-SMase and N-SMase activities. These results suggest that avicin G alters cellular SM/Cer 
balance by increasing SM levels (Figure 15A). A previous study showed that when cellular 
SM level is increased by fendiline treatment, a functional inhibitor of A-SMase, 
supplementation with exogenous Cer returns K-Ras and PS to the PM (Cho et al., 2015). 
Therefore, to test whether the mechanism by which avicin G-mediated K-Ras and PS 
mislocalization is through altering SM/Cer balance, we performed a set of lipid add-back 
experiments with exogenous Cer. 
 
MDCK cells stably co-expressing mGFP-K-RasG12V or -LactC2 with mCherry-CAAX were 
treated with DMSO (control) or avicin G for 48h and further incubated with Cer (10µM) in 
the presence of DMSO (control) or avicin G (Figure 16). Cells were fixed in 4% PFA at 
different time points and imaged with a confocal microscope. Manders coefficient values 
were used to quantify K-RasG12V and LactC2 mislocalization at different time points after 
exogenous Cer addition (Figure 16C and D). We found that in avicin G-treated cells, mGFP-
K-RasG12V and -LactC2 partially returns to the PM within 15 min after exogenous Cer 
supplementation (Figure 16A and B). Taken together, our data suggest that perturbation  
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MDCK cells stably co-expressing (A) mGFP-K-RasG12V or (B) -LactC2 with mCherry-
CAAX were treated with DMSO (control) or avicin G for 48h and further incubated in 
the presence of Cer (10µM) with DMSO (control) or avicin G. Cells were fixed with 4% 
PFA at different time points and imaged with a confocal microscope. Representative 
images of incubation with Cer at each time points are shown. The graphs show 
Manders coefficient values used measure for mislocalization of (C) K-RasG12V and 
(D) LactC2 from the PM at different time points from three independent experiments. 
 
Figure 19. Supplementation with exogenous Cer returns K-Ras and PS to the PM 
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of cellular SM/Cer balance by avicin G treatment mislocalizes K-Ras and PS, and that 
cellular SM/Cer balance is important for maintaining K-Ras and PS in the PM. 
III. Characterize the role of avicin as an anti-K-Ras cancer drug 
Previous studies have shown that avicin has anti-cancer effects which induce tumor cell 
death, lower energy metabolism in tumors and inhibit activation of NF-κB (Haridas, 
Arntzen, et al., 2001; Haridas, Higuchi, et al., 2001; Haridas et al., 2007; H. Wang et al., 
2010). Avicin triggers apoptosis by mitochondrial perturbation and Fas-mediated 
receptor cell death (H. Wang et al., 2010). However, the mechanism by which avicin 
disrupts cancer cell growth is still not fully understood. We have previously shown that 
avicin G mislocalizes K-Ras and PS from the PM. Since K-Ras must be localized to the PM 
for its activity, we looked at the effects of avicin G treatment on K-Ras downstream signal 
output and cell proliferation in K-Ras-addicted cancer cells. 
A. Avicin G blocks Ras downstream signaling 
We looked at the effects of avicin G treatment on oncogenic K-Ras signaling in the Raf-
MEK-ERK and PI3K-AKT signaling pathways and measured for phosphorylation of ERK and 
Akt by western blot analysis. MDCK cells stably expressing mGFP-K-RasG12V or -H-
RasG12V were treated with DMSO (control) or avicin G for 48h. Whole cell lysates were 
harvested and western blot analysis was performed to measure phosphorylated ERK and 
Akt (S473) using phospho-specific antibodies (Figure 20). Our data show that avicin G 
treatment significantly reduces both ppERK and pAkt (S473) levels dose-dependently in 
K-RasG12V cells (Figure 20A). Furthermore, we tested the effect of avicin G on the protein  
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MDCK cells expressing (A) mGFP-K-RasG12V or (B) -H-RasG12V were treated with 
DMSO (control) or avicin G for 48h. Whole cell lysates were harvested and western 
blot analysis was performed to detect ppERK and pAkt (S473) protein expression 
levels. Total ERK and Akt were used as loading controls. The graphs show the mean 
ppERK and pAkt (S473) from three independent experiments. (C) anti-GFP was 
used to detect total mGFP-K-RasG12V or -H-RasG12V protein expression levels. 
Actin was used as a loading control. One-way ANOVA test was performed to 
determine the significant differences (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001, N.S. – not significant) between DMSO (control) treated and avicin G 
treated cells. 
Figure 20. Avicin G blocks Ras downstream signaling 
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expression level of total mGFP-K-RasG12V and -H-RasG12V by performing western blot 
analysis against anti-GFP antibody. Our data showed avicin G treatment significantly 
increased the protein expression level of mGFP-K-RasG12V, but not mGFP-H-RasG12V 
(Figure 20C). 
B. Avicin G reduces cell proliferation in K-Ras-addicted cancer cells 
We showed that avicin G treatment blocks oncogenic Ras signaling, which suggests avicin 
may have anti-cancer activity. The growth and survival of some cancers can be inhibited 
by the inactivation of a single oncogene which they depend on (Weinstein & Joe, 2006). 
This dependency on specific oncogenes for maintaining their cancer phenotypes is 
referred to as oncogene addiction (Weinstein & Joe, 2006). K-Ras-dependent or -addicted 
cancers require oncogenic mutant K-Ras expression for their cell growth and survival, 
while K-Ras-independent cancers do not. (Hayes et al., 2016; A. Singh et al., 2009). 
 
To validate the effects of avicin as an anti-cancer drug, we performed proliferation assay 
on non-small cell lung cancer cells (NSCLCs) and pancreatic ductal adenocarcinoma cells 
(PDACs) expressing oncogenic mutant K-Ras. For control cells we used K-Ras wild-type 
NSCLC (H1299) and PDAC (BxPC-3) cells. For oncogenic mutant K-Ras NSCLCs, we used K-
Ras-independent (H23 and A549) and K-Ras-dependent (H358 and H441) cells (A. Singh 
et al., 2009). For oncogenic mutant K-Ras PDACs, we used K-Ras-dependent (AsPC-1, Panc 
10.05, MiaPaCa-2, HPAF-II, and PANC-1) cells (Hayes et al., 2016). We seeded NSCLCs or 
PDACs (1.0 x 104) to a 96-well plate and treated with DMSO (control) or avicin G (1.25µM) 
for 72h. After the treatment, cell growth was measured by proliferation assay. Our data 
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show that avicin G significantly reduced the growth of oncogenic K-Ras-dependent 
NSCLCs and PDACs (Figure 21). However, K-Ras-independent NSCLCs cell growth were 
unaffected by avicin G treatment (Figure 21A). Taken together, avicin G treatment 
significantly reduces cell growth in K-Ras-addicted NSCLCs and PDACs. 
 
 
  
 
 
54 
 
 
 
 
A.             B. 
  
 
 
 
  
 
K-Ras expressing (A) non-small cell lung cancer (NSCLCs) and (B) pancreatic 
ductal adenocarcinoma (PDAC) cells were seeded (1.0 x 104) to a 96-well plate 
and treated with DMSO (control) or avicin G (1.25µM) for 72h. After 5 days, cell 
growth was measured by CyQUANT NF Cell Proliferation Assay Kit (C35006). The 
graph shows the mean +/- S.E.M. cell proliferation from three independent 
experiments. Open bars represent cancer cell lines expressing wild-type K-Ras. 
Closed bars represent cancer cells expressing oncogenic K-Ras. Mann-Whitney U 
test was used to measure significant differences (*** p<0.001, **** p<0.0001, 
N.S. – not significant) between DMSO (control) treated cells and avicin G treated 
cells. 
Figure 21. Avicin G inhibits cell proliferation in K-Ras-addicted cancer cells 
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DISCUSSION AND FUTURE DIRECTIONS 
Our lab focuses on disrupting K-Ras PM interaction and its signaling since K-Ras must be 
localized to the PM for its biological activity. Therefore, identifying compounds that 
disrupt this interaction from occurring can serve as a good starting point for developing 
anti-K-Ras drugs. We identified avicin in a high content cell-based screen of chemical 
libraries for compounds that disrupt K-Ras interaction at the PM.  
 
Avicin are natural plant-derived triterpenoid saponins extracted from Acacia victoriae and 
exhibit tumor inhibitory activity (Jayatilake et al., 2003). Triterpenoid saponins are highly 
producible secondary metabolites found among many natural-derived sources such as 
plants, marine organisms, and microbes (Bayat Mokhtari et al., 2017; Newman et al., 
2002). Avicin D has previously been well characterized to target mitochondria function by 
permeabilizing its outer membrane and results in high levels of reactive oxygen species 
(ROS), which sensitizes tumor cells to cytotoxic effects (Hanausek et al., 2001; Haridas, 
Higuchi, et al., 2001; Haridas et al., 2011; Lemeshko, Haridas, Quijano Perez, & 
Gutterman, 2006). Avicin D treatment particularly has a profound effect on cancer cellular 
metabolism by selectively inducing apoptosis and autophagy (H. Wang et al., 2010; Z. X. 
Xu et al., 2007; Zhang et al., 2008). In 2015, avicin D was designated as an orphan drug by 
the Federal Food and Drug Administration (FDA) for treatment of multiple myeloma (U.S. 
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Food and Drug Administration; https://www.accessdata.fda.gov/scripts/opdlisting/ 
oopd/detailedIndex.cfm?cfgridkey=467714). Furthermore, a previous study measured 
the inhibitory effects of avicin G, the other avicin isomer on cell growth in fission yeast, 
Szhizosaccharomyces pombe and Saccharomyces cervisiae (Gutterman et al., 2005). They 
discovered that avicin G were more cytotoxic to S. pombe and significantly reduced its cell 
growth, integrity, and cytokinesis at low concentrations (Gutterman et al., 2005).  
 
Our approach is to use avicin to target oncogenic K-Ras activity by disrupting its 
interaction with the PM and blocking its oncogenic activity. We show that avicin G (IC50 
73.8nM) is more potent at mislocalizing K-Ras from the PM than avicin D (IC50 142.2nM) 
(Figure 10). We found that avicin G translocates K-Ras to lysosomes and other 
endomembranes (Figure 11). We further showed that avicin G treatment increases total 
GFP-K-RasG12V levels (Figure 20C). These data suggest that K-Ras degradation process is 
disrupted once K-Ras is translocated to lysosomes after avicin G treatment. Avicin G could 
be a useful tool to elucidate the not-yet characterized K-Ras degradation mechanism.  
 
Furthermore, we show that avicin G preferentially mislocalizes K-Ras over H-Ras and K-
Ras4A isoforms (Figure 12). Therefore, avicin G can specifically perturb K-Ras PM 
interactions. While the mechanism by which K-Ras traffics from the ER to the PM is still 
unclear, two known mechanisms in which K-Ras PM interaction can be blocked are: 1) 
enhancing K-Ras phosphorylation (Bivona et al., 2006; Cho, Casteel, et al., 2016) and 2) 
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reducing PS content from the PM (Cho et al., 2012; Cho, van der Hoeven, et al., 2016; 
Yeung et al., 2008). 
 
It was found that protein kinase C (PKC) and protein kinase G (PKG) phosphorylate K-Ras 
at Ser 181, as well as Ser 171 and Thr 181 (to a lesser extent) in its polybasic domain, 
resulting in the dissociation of K-Ras from the PM (Bivona et al., 2006; Cho, Casteel, et al., 
2016). To test whether avicin mislocalizes K-Ras from the PM through K-Ras 
phosphorylation, we used K-Ras mutant (Ser181Ala, Ser171Ala, Thr181Ala) that is 
insensitive to its phosphorylation, termed K-RasG12V AAA. We found that avicin G 
treatment mislocalizes K-RasG12V AAA from the PM (IC50 74.7nM) (Figure 13). 
Considering IC50 value for K-RasG12V AAA is within a similar range as K-RasG12V (IC50 
73.2nM), our data suggest that avicin-mediated K-Ras PM mislocalization is independent 
of K-Ras phosphorylation. To further validate this, we can test the role of PKC and PKG on 
K-Ras phosphorylation in avicin-treated cells. We can examine PKC and PKG activities by 
measuring the phosphorylation of myristoylated alanine-rick C kinase substrate 
(MARCKS) or vasodilator stimulated phosphoprotein (VASP), respectively. If avicin 
mediates K-Ras phosphorylation through PKC and/or PKG, we expect to observe 
increased phosphorylation of MARCKS and VASP, respectively. Furthermore, we can 
directly measure K-Ras phosphorylation after avicin treatment using 
immunoprecipitation assay. 
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As stated earlier, it is known that K-Ras polybasic domain electrostatically interacts with 
anionic PS and reduction of PS mislocalizes K-Ras from the PM (Cho et al., 2012; Cho, van 
der Hoeven, et al., 2016; Yeung et al., 2008). To further investigate avicin-mediated K-Ras 
PM mislocalization, we used LactC2 as a marker for PS and found that avicin G 
redistributes LactC2 from the PM, suggesting PS is mislocalized (Figure 14). Interestingly, 
the IC50 of avicin G treated LactC2 cells (IC50 69.7nM) is within a similar range as K-
RasG12V cells (IC50 73.8nM). This suggests that avicin G-mediated PM mislocalization of 
K-Ras and PS may share the same molecular pathway.  
 
Recent studies have shown that functional A-SMase inhibitors, such as fendiline and 
tricyclic anti-depressants, mislocalize K-Ras and PS from the PM through dysregulating 
sphingomyelin (SM) and ceramide (Cer) metabolism (Cho, van der Hoeven, et al., 2016; 
van der Hoeven et al., 2013; van der Hoeven et al., 2018). To further investigate the 
mechanism by which avicin mislocalizes K-Ras and PS from the PM, we looked at SMase 
activity after avicin G treatment. We found that avicin G significantly inhibits N-SMase 
activity at lower concentrations ( ³ 5nM), whereas A-SMase activity is inhibited only at 
higher concentrations (³ 500nM) (Figure 16). Furthermore, our data show that avicin G 
increases SMPD2 expression levels at low concentrations (> 5nM) in a dose-dependent 
manner, but decreases SMPD1 expression levels at higher concentrations (> 500nM). 
Avicin G also disrupted cellular localization of SMPD1 and SMPD2 (Figures 17 and 18). Our 
data suggest that avicin G is a SMPD2-specific inhibitor at a low concentration, but a 
general SMPD inhibitor at higher concentrations. For SMPD3, avicin G does not alter the 
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expression level and cellular localization. A recent study showed that SMPD3 possesses 
an N-terminal hydrophobic lipid-binding domain that binds to PS and is required for 
stimulating its full activity (Airola et al., 2017). We showed that avicin G mediates PS 
redistribution from the PM (Figure 14). Taken together, we hypothesize that avicin G also 
inhibits SMPD3 activity by reducing cellular PS content.  
 
Previous studies have shown that inhibition of A-SMase results in altered cellular SM and 
Cer levels (Cho, van der Hoeven, et al., 2016; van der Hoeven et al., 2018). We found that 
after avicin G treatment, cellular SM levels increase and substantially accumulates to 
intracellular vesicles (Figure 15). Therefore, we hypothesize that disrupting cellular 
SM/Cer balance by inhibiting SMases may be a putative mechanism for avicin-mediated 
K-Ras and PS mislocalization from the PM (Figure 22A). To further validate this, we 
supplemented avicin G-treated cells with exogenous Cer in the continuous presence of 
avicin G and found that both K-Ras and LactC2 partially return to the PM immediately 
after 15 min incubation (Figures 19 and 22). This suggests that SM/Cer balance is 
important for K-Ras and PS localization at the PM and may serve as a novel therapeutic 
target for blocking K-Ras activity (Figure 22). Moreover, the role of sphingolipid 
metabolism in regulating K-Ras function can be investigated further. Inhibiting SMases 
constitutes only one of several ways for increasing cellular SM levels. SM can be produced 
by its de novo biosynthesis pathway mediated by the serine palmitoyltransferase (SPT) 
complex (Maekawa, Lee, Wei, Ridgway, & Fairn, 2016). Previous studies have shown that 
treatment with staurosporine, a PS trafficking inhibitor, results in increased cellular SM  
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(A) Avicin G treatment disrupts SM/Cer balance by increasing cellular SM levels and 
mislocalizing K-RasG12V and LactC2 from the PM. (B) Supplementation with 
exogenous Cer to avicin G-treated cells restore SM/Cer balance and partially returns 
K-RasG12V and LactC2 to the PM. 
Figure 22. SM/Cer balance is important for K-Ras and PS PM localization 
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levels by decreasing abundance of ORMDL3, a Cer sensor and negative regulator in the 
SPT-mediated sphingolipid biosynthesis pathway (Cho, Park, & Hancock, 2013; Cho et al., 
2012; Maekawa et al., 2016). We hypothesize that in addition to the inhibited SMase 
activities by avicin G, the compound could also decrease ORMDL3 levels, resulting in the 
increased SM levels our data shows (Figure 15). Immunoblot analysis to measure ORMDL3 
expression level in avicin G-treated cells will answer this question.  
 
While we have shown the anti-K-Ras activity of avicin G in blocking oncogenic K-Ras 
downstream signaling, we also showed its anti-H-Ras activity (Figure 20A and 20B). For H-
RasG12V signaling, we showed that avicin G treatment significantly reduces Akt 
phosphorylation (S473), whereas the treatment shows, albeit not significant, a trend of 
decreased ERK phosphorylation (Figure 20B). Previous studies have shown that H-Ras 
signaling is regulated by lipid rafts, which are made up of sphingolipids and cholesterol 
(Plowman, Muncke, Parton, & Hancock, 2005). We hypothesize that the reduced levels of 
phospho-ERK and -Akt in H-RasG12V-expressing cells are through perturbation of lipid 
rafts by dysregulated cholesterol contents at the PM. Recent studies showed that A-
SMase activity regulates lipid raft size and function, and inhibition of A-SMase reduces 
cholesterol content at the PM (Cho, van der Hoeven, et al., 2016; Gilbert, Loranger, 
Omary, & Marceau, 2016; Zeidan & Hannun, 2007). In addition, considering sphingolipids 
are also key components to lipid raft composition, the effect of avicin G in disrupting 
SM/Cer balance may influence lipid raft formation and thereby H-Ras signaling. To 
 
 
62 
validate this, further electron confocal microscopy using GFP-tH, a lipid raft marker, needs 
to be performed to study the integrity of lipid rafts in avicin-treated cells.  
 
We tested the anti-cancer activity of avicin G by measuring the proliferation of oncogenic 
mutant K-Ras expressing NSCLCs and PDACs. We found that the cell proliferation of 
NSCLCs and PDACs which require oncogenic mutant K-Ras expression for their cell growth, 
or K-Ras-dependent, are significantly reduced after avicin G treatment (Figure 21). 
Interestingly, we found that K-Ras-dependent NSCLCs (H358 and H441) are more sensitive 
to avicin G treatment than K-Ras-dependent PDACs (AsPC-1, Panc 10.05, MiaPaCa-2, 
HPAF-II, and PANC-1). To validate the effect of avicin G treatment on K-Ras-dependency, 
we also treated wild-type K-Ras (H1299) and K-Ras-independent (H23 and A549) NSCLCs, 
which do not require K-Ras for their cell growth, with avicin G and found no significant 
reduction in their cell proliferation. Our results suggest that avicin G has significant anti-
cancer effects in K-Ras-dependent cancers. Previous studies have shown that treatment 
with A-SMase-specific inhibitors significantly reduced cell proliferation of pancreatic, 
lung, and colon cancer cells (Cho, van der Hoeven, et al., 2016; van der Hoeven et al., 
2013; van der Hoeven et al., 2018). However, little is known about the effects of N-SMase 
on cell proliferation of K-Ras-dependent cancers. Therefore, testing N-SMase-specific 
inhibitors on the cell growth of K-Ras-dependent NSCLCs and PDACs could bring to light 
the importance of N-SMases in K-Ras-expressing cancers and support the anti-cancer 
properties of avicin. 
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In conclusion, we demonstrated that avicin G mislocalizes K-Ras and PS from the PM 
through perturbing cellular balance of SM and Cer by inhibiting A-SMase and N-SMase. 
We further show that avicin G significantly reduces K-Ras signal output and cell 
proliferation of K-Ras-dependent NSCLCs and PDACs, suggesting its role as an anti-K-Ras 
drug. Taken together, this study identifies that avicin is a potent SMase inhibitor, and that 
the cellular balance of SM and Cer plays a critical role for K-Ras PM interaction and its 
activity. Ultimately, these findings provide further insight towards the development of 
anti-K-Ras cancer drugs.  
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